Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - deferasirox, quantity: 500 mg - tablet, dispersible - excipient ingredients: hydrogenated castor oil; sodium lauryl sulfate; hyprolose; microcrystalline cellulose; hypromellose; dibasic sodium phosphate; magnesium stearate; colloidal anhydrous silica; crospovidone - deferasirox is indicated in the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. it is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective. ,deferasirox is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - deferasirox, quantity: 250 mg - tablet, dispersible - excipient ingredients: colloidal anhydrous silica; hydrogenated castor oil; hypromellose; crospovidone; magnesium stearate; sodium lauryl sulfate; dibasic sodium phosphate; microcrystalline cellulose; hyprolose - deferasirox is indicated in the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. it is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective. ,deferasirox is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - deferasirox, quantity: 500 mg - tablet, dispersible - excipient ingredients: dibasic sodium phosphate; colloidal anhydrous silica; microcrystalline cellulose; crospovidone; magnesium stearate; hypromellose; hydrogenated castor oil; sodium lauryl sulfate; hyprolose - deferasirox is indicated in the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. it is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective. ,deferasirox is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - deferasirox, quantity: 125 mg - tablet, dispersible - excipient ingredients: sodium lauryl sulfate; crospovidone; hypromellose; microcrystalline cellulose; hydrogenated castor oil; dibasic sodium phosphate; magnesium stearate; hyprolose; colloidal anhydrous silica - deferasirox is indicated in the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. it is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective. ,deferasirox is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - deferasirox, quantity: 500 mg - tablet, dispersible - excipient ingredients: microcrystalline cellulose; sodium lauryl sulfate; hydrogenated castor oil; magnesium stearate; hyprolose; crospovidone; dibasic sodium phosphate; colloidal anhydrous silica; hypromellose - deferasirox is indicated in the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. it is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective. ,deferasirox is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - topiramate, quantity: 200 mg - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; microcrystalline cellulose; sodium starch glycollate; pregelatinised maize starch; titanium dioxide; hypromellose; polysorbate 80; iron oxide yellow; macrogol 400 - epilepsy: topiramate is indicated in adults and children 2 years and over: - as monotherapy in patients with newly diagnosed epilepsy, - for conversion to monotherapy in patients with epilepsy, and - as add-on therapy in partial onset seizures (with or without secondary generalised seizures), primary generalised tonic-clonic seizures or drop attacks associated with lennox-gastaut syndrome. migraine: topiramate is indicated for the prophylaxis of migraine headache in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - topiramate, quantity: 100 mg - tablet, film coated - excipient ingredients: magnesium stearate; pregelatinised maize starch; sodium starch glycollate; microcrystalline cellulose; lactose monohydrate; titanium dioxide; hypromellose; polysorbate 80; macrogol 400 - epilepsy: topiramate is indicated in adults and children 2 years and over: - as monotherapy in patients with newly diagnosed epilepsy, - for conversion to monotherapy in patients with epilepsy, and - as add-on therapy in partial onset seizures (with or without secondary generalised seizures), primary generalised tonic-clonic seizures or drop attacks associated with lennox-gastaut syndrome. migraine: topiramate is indicated for the prophylaxis of migraine headache in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - topiramate, quantity: 50 mg - tablet, film coated - excipient ingredients: lactose monohydrate; pregelatinised maize starch; sodium starch glycollate; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; polysorbate 80; iron oxide yellow; macrogol 400 - epilepsy: topiramate is indicated in adults and children 2 years and over: - as monotherapy in patients with newly diagnosed epilepsy, - for conversion to monotherapy in patients with epilepsy, and - as add-on therapy in partial onset seizures (with or without secondary generalised seizures), primary generalised tonic-clonic seizures or drop attacks associated with lennox-gastaut syndrome. migraine: topiramate is indicated for the prophylaxis of migraine headache in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - topiramate, quantity: 25 mg - tablet, film coated - excipient ingredients: magnesium stearate; sodium starch glycollate; microcrystalline cellulose; pregelatinised maize starch; lactose monohydrate; titanium dioxide; hypromellose; polysorbate 80; macrogol 400 - epilepsy: topiramate is indicated in adults and children 2 years and over: - as monotherapy in patients with newly diagnosed epilepsy, - for conversion to monotherapy in patients with epilepsy, and - as add-on therapy in partial onset seizures (with or without secondary generalised seizures), primary generalised tonic-clonic seizures or drop attacks associated with lennox-gastaut syndrome. migraine: topiramate is indicated for the prophylaxis of migraine headache in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - verapamil hydrochloride, quantity: 180 mg - tablet, modified release - excipient ingredients: microcrystalline cellulose; sodium alginate; povidone; magnesium stearate; hypromellose; macrogol 400; macrogol 6000; purified talc; glycol/butylene glycol montanate; titanium dioxide; iron oxide red - modified release tablets,isoptin sr is indicated for the management of hypertension and angina pectoris.